ClinicalTrials.gg
CompletedNCT06973720VESPER-3Updated Nov 5, 2026

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

A Phase 2 interventional study of MET097 and Placebo in Obesity and Overweight or Obesity, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Updated Nov 5, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Enrollment
10th of 21
268 · median 258
Started
2025
with 3 others
Phase 2
3 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
20 of 21
Pfizer

Among the 21 studies testing berobenatide in Obesity, this one is the 10th largest by enrollment, is one of 4 that started in 2025, is one of 3 in phase 2, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of multiple once monthly (QM) dose levels of MET097 after 12 once weekly (QW) doses, compared to placebo. The study will include adult participants with obesity or overweight. Participants will initially receive once weekly MET097 with or without titration or placebo for 12 weeks. Participants will then transition to a four-fold higher monthly dose for a total of 13 monthly doses. The primary endpoint is at Week 28, four weeks after the fourth monthly dose. All participants will be followed for \~5 half-lives after administration of the last dose for safety.

03

Conditions studied

  • Obesity
  • Overweight or Obesity

Keywords

  • Overweight
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) at Screening of:

    • BMI ≥30 kg/m2 and ≤50.0 kg/m2 (can have the weight-related co-morbidities listed below)
    • BMI ≥27.0 kg/m2 to \<30.0 kg/m2 with at least one of the following weight-related co-morbidities:

      1. Hypertension: on blood pressure (BP)-lowering medication or having systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg at Screening
      2. Dyslipidemia: on lipid-lowering medication or having low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7 mmol/L), or high-density lipoprotein-cholesterol (HDL-C) \<40 mg/dL (1.0 mmol/L) for men or HDL-C \<50 mg/dL (1.3 mmol/L) for women at Screening
      3. Stable body weight (increase or decrease ≤5 kg) within 3 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes (T1DM or T2DM) or A1c (HbA1c) ≥ 6.5% or fasting plasma glucose >125 mg/dL.
  • Estimated (eGFR) \<75 mL/min/1.73 m2
  • History of pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Poorly controlled hypertension at, defined as any of the following:

    • Mean seated systolic BP ≥160 mm Hg or mean seated diastolic BP ≥95 mm Hg at Screening visit
    • A change in antihypertensive medications within 30 days of Screening visit
    • Renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension at Screening; postural hypotension is defined as a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of 10 mmHg, with or without symptoms during the assessment, within three minutes of standing
  • Thyroid-stimulating hormone (TSH) level lower than 0.4 mIU/L or higher than 6.0 mIU/L at the Screening visit. Note: participants receiving treatment for hypothyroidism may be included, provided their thyroid hormone replacement dose has been stable for at least 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    MET097

    Participants will be randomized to one of four dosing regimens receiving twelve weekly doses of MET097 (with or without titration) followed by multiple monthly doses.

    Drug: MET097

  • Placebo comparator
    Placebo

    Participants who are randomized to the placebo arm will receive twelve weekly doses of placebo followed by multiple monthly doses.

    Drug: Placebo

Interventions

  • DrugMET097

    For subcutaneous administration.

  • DrugPlacebo

    Sterile 0.9% (w/v) saline for subcutaneous administration.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight at Week 28

    Evaluate the efficacy at Week 28 of four dose regimens of QW MET097 switching to QM compared to placebo.

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

Secondary outcomes

  1. Percent change from baseline in body weight at Week 64

    Time frame: Baseline (Week 0) through Week 64 (Day 449)

  2. Percent change from baseline in body weight at all other post-baseline weight measurements up to Week 64 other than Week 28

    Time frame: Baseline (Week 0) through Week 24 (Day 169); Week 32 (Day 225) through Week 64 (Day 449)

  3. Change from baseline in absolute bodyweight (in kg) at all protocol-specified weekly and monthly post-baseline measurements

    Time frame: Baseline (Week 0) through Week 64 (Day 449)

  4. Change from baseline in body mass index (BMI) at all protocol-specified weekly and monthly post-baseline measurements

    Time frame: Baseline (Week 0) through Week 64 (Day 449)

  5. Change from baseline in waist circumference (in cm) at all protocol-specified weekly and monthly post-baseline measurements

    Time frame: Baseline (Week 0) through Week 64 (Day 449)

  6. Percent change from baseline in body weight at post-treatment follow-up

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  7. Change from baseline in absolute bodyweight (in kg) at post-treatment follow-up

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  8. Change from baseline in body mass index (BMI) at post-treatment follow-up

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  9. Change from baseline in waist circumference (in cm) at post-treatment follow-up

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  10. Occurrence of treatment emergent adverse events (TEAEs)

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  11. Minimum observed concentration (Cmin)

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  12. Area under the concentration versus time curve during the dosing interval (AUC)

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  13. Maximum observed concentration (Cmax)

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

  14. Time to maximum concentration (Tmax)

    Time frame: Baseline (Week 0) through Week 72 (Day 505)

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Dec 2025, 8 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 15, 2025
StartActual
Apr 7, 2025
Primary completionActual
Dec 16, 2025
CompletionActual
Oct 19, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Sites
1 site added
Show site
  • CenExel iResearch, LLC · Decatur, United States
Nov 5, 2026
Study completion
Oct 16, 2026→Oct 19, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    1 site added
    Show site
    • CenExel iResearch, LLC · Decatur, United States
    Study completion Oct 16, 2026→Oct 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06973720
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Apr 7, 2025
Primary completion
Dec 16, 2025
Completion
Oct 19, 2026
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion